Clinical trial NCT06120335: Development of a Scale for Cancer Patients' Willingness to Voluntarily Participate in Drug Clinical Trials
Official title: Development and Reliability and Validity Evaluation of a Scale for Cancer Patients' Willingness to Voluntarily Participate in Drug Clinical Trials
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Keywords: drug clinical trials
cancer patients
willingness
Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2023-11-07
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult tumor patients treated at Sun Yat sen Memorial Hospital at Sun Yat sen University

Brief summary: The goal of this observational study is to develop a scale for cancer patients' willingness to voluntarily participate in drug clinical trials and evaluate its reliability and validity.

Detailed description: Inclusion Criteria:

1. Age 18-80 years old (including boundary values).
2. Tumor patients with clear diagnosis.
3. Whether they finally sign the informed consent form of one drug clinical trial or not, and whether they are finally enrolled in one drug clinical trial or not, patients who have undergone the informed consent process of drug clinical trials conducted by clinicians can be enrolled in this study.
4. Volunteer to participate in this study and sign an informed consent form.

Exclusion Criteria:

1. Patients with unclear consciousness.
2. Patients who are unable to correctly understand and answer questions.
3. Vulnerable subjects include: students and subordinates of researchers, military personnel, prisoners, patients with incurable diseases, patients in critical situations, those admitted to welfare institutions, homeless individuals, minors, and those who are unable to provide informed consent.

Eligibility criteria: Inclusion Criteria:

1. Age 18-80 years old (including boundary values).
2. Tumor patients with clear diagnosis.
3. Whether they finally sign the informed consent form of one drug clinical trial or not, and whether they are finally enrolled in one drug clinical trial or not, patients who have undergone the informed consent process of drug clinical trials conducted by clinicians can be enrolled in this study.
4. Volunteer to participate in this study and sign an informed consent form.

Exclusion Criteria:

1. Patients with unclear consciousness.
2. Patients who are unable to correctly understand and answer questions.
3. Vulnerable subjects include: students and subordinates of researchers, military personnel, prisoners, patients with incurable diseases, patients in critical situations, those admitted to welfare institutions, homeless individuals, minors, and those who are unable to provide informed consent.

Primary outcomes:
measure: A semi-structured interview
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen Memorial Hospital
state: Guangdong
Study officials:
References: